Showing 1011-1020 of 6907 results for "".
Hepatitis C Treatment: Grim Fiscal Prospects?
https://reachmd.com/programs/gi-insights/hepatitis-c-treatment-grim-fiscal-prospects/2947/We are developing increasingly effective therapies for patients with chronic hepatitis C, yet many physicians who treat a high volume of these patients are struggling to maintain economically viable strategies for providing care. Is treatment of hepatitis C becoming a money-losing proposition? Can aEducation, Research & NIH's Beleagured Budget
https://reachmd.com/programs/clinicians-roundtable/education-research-nihs-beleagured-budget/2943/The need for a sustained investment in medical research is critical to patient care. But annual budget cuts to the National Insitutes of Health have continued for years now. Dr. Darrell Kirch, president and CEO of the Association of American Medical Colleges tells the Chicago Tribune's Bruce JapsenStarting or Purchasing A Medical Practice
https://reachmd.com/programs/clinicians-roundtable/starting-or-purchasing-a-medical-practice/2917/Are you planning on starting up or purchasing a new medical practice? If so, you will not want to miss this segment in which medical practice consultant Marc Halley talks about the considerations that should go into starting or purchasing a practice. Do you want partners? Where do you want to live?The Root of Tooth Regeneration and Stem Cells
https://reachmd.com/programs/clinicians-roundtable/the-root-of-tooth-regeneration-and-stem-cells/2895/What are the mechanisms behind animal tooth regeneration, and what can tooth stem cell research tell us? Your host, Dr. Bruce Bloom and Dr. Ophir Klein, of the Biomedical Sciences Graduate Program at the University of California, San Francisco discuss stem cell research and the potential clinical apComplementary Medicine & Pediatrics: Part 1
https://reachmd.com/programs/clinicians-roundtable/complementary-medicine-pediatrics-part-1/2706/Are your patients asking you about alternative medicine approaches? Do you know enough to offer them answers or alternatives that may complement a particular treatment? Join pediatrician Dr. Kathi Kemper talking with host Dr. Bill Rutenberg about resources and training programs available in alternatPostpartum Depression vs. the Baby Blues
https://reachmd.com/programs/advances-in-womens-health/postpartum-depression-vs-the-baby-blues/2677/Postpartum depression and postpartum blues are vastly different clinical concerns, yet the former is often simply viewed (and treated) as a more severe version of the latter. Dr. Nehama Dresner, associate professor of clinical psychiatry, behavioral sciences, and obstetrics and gynecology at NorthweInsurance Coverage and Late Stage Cancer Diagnosis
https://reachmd.com/programs/clinicians-roundtable/insurance-coverage-and-late-stage-cancer-diagnosis/2671/Having low-quality health insurance, or a complete lack of insurance is certainly detrimental to patients' health; yet is there any hard data to properly correlate an association? Dr. Elizabeth Ward, from the American Cancer Society explores the relationship with Dr. Lee Freedman, citing a recent AManagement of Small Renal Tumors
https://reachmd.com/programs/clinicians-roundtable/management-of-small-renal-tumors/2634/Small Renal tumors: Are patients being properly counseled? With your host, Dr. Gary Kohn, is Robert "Houston" Thompson, Urologic Oncology Fellow, at Memorial Sloan Kettering Cancer Center in New York. Join the discussion as Dr. Thompson covers the management of small renal tumors, highlighting surviNon-Steroidal, Topical Anti-Inflammatories
https://reachmd.com/programs/clinicians-roundtable/non-steroidal-topical-anti-inflammatories/2598/Dr. Michael Greenberg interviews Dr. Mark Lebwohl, Professor of Dermatology from the Mount Sinai School of Medicine in New York. Dr. Lebwohl discusses Protopic, Elidel, the myths and realities behind their safety for patients.New Drugs for Patients With Multiple Sclerosis
https://reachmd.com/programs/clinicians-roundtable/new-drugs-for-patients-with-multiple-sclerosis/2549/Dr. John Richert discusses 6 approved drugs that have changed the lives of the young patients who have this disabling disease. The early diagnosis of multiple sclerosis and the prompt institution of therapy is beginning to show dividends in that the disease does not progress as rapidly.